TFA UPDATES & COVERAGE
Corporate disclosures, PR Newswire releases and coverage published under current and historical names.
CORPORATE DISCLOSURE
Primary sources are SEC filings, OTC Markets, and formal company announcements.
TFA’s China licensee HuanZhang has entered Shanghai Pharma’s Antrodia camphorata raw-material supply chain and, as of September 18, 2026, was the program’s only qualified supplier, adding quality and supply-chain experience relevant to TFA-01 development in China.
Read the full releaseTFA completed a preliminary 14-day repeat-dose study of TF-15 in rats, with the summary report signed on July 2, 2026. The company is continuing safety, toxicology, and formulation research to support TFA-01.
Read the full releaseTFA's early observations in 15 dogs included improvements in walking and mobility in selected cases. Individual case records described a return to walking around day 7 and improved mobility with discharge around day 14. These time points do not represent outcomes for the full group.
Read the full releaseTFA can currently supply approximately 100 kilograms of cultured material per month and reports internal batches with consistent Antcin A content of at least 3,000 ppm on a dry-weight basis. These figures describe cultured material supply and content, not finished drug production capacity.
Read the full releaseTFA-01 targets canine osteoarthritis as its initial indication. Injectable formulation and safety studies are underway, along with preparations for a third-party canine osteoarthritis study.
Read the full releaseTFA furnished a Form 6-K to the SEC on September 2, 2026, outlining an offshore private placement at US$2.52 per share. The target is approximately US$10 million, with a maximum of approximately US$15 million.
Proceeds are intended to support TFA-01 manufacturing and quality controls, nonclinical safety and toxicology, clinical and regulatory work, as well as personnel, working capital, capital-markets readiness and offering expenses.
As of the report date, the offering remained open, and the company could conduct one or more closings. For information only; not an offer to sell or a solicitation to buy securities.
Read the SEC disclosureThe corporate name change became effective on July 23, 2026, and was reported on Form 6-K on July 27.
Name used at publicationTFA Therapeutics, Inc.
The filing describes the cooperation framework for TFA-01 and the Antcin A platform.
Name used at publicationCordyceps Sunshine Biotech Holdings Co., Ltd.
PR NEWSWIRE ARCHIVE
Company-commissioned releases, with regional editions grouped under each original.
Historical company release outlining plans for veterinary drug development and regulatory applications.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release reporting preliminary combination-study findings; clinical efficacy had not been established.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release describing the drug candidate and market plans at the time.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release describing the company’s goals for raw-material supply and retail-channel expansion.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release documenting the move to OTCQB and the company’s capital-markets plans at the time.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release documenting KASAER’s strategic retail partnership in Hong Kong.
Name used at publicationC.S Group / KASAER (天草・噶薩爾)
Historical company release documenting DTC eligibility for the company’s shares.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release outlining the company’s development strategy for Antrodia cinnamomea and related markets in Greater China.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release documenting a milestone in the company’s U.S. public-market development.
Name used at publicationC.S Group / Cordyceps Sunshine
Historical company release documenting the company’s public-market positioning and development before its name change.
Name used at publicationCordyceps Sunshine / C.S Group
MEDIA ARCHIVE
Coverage from Taiwanese television and business media; partnership content and company-held clips are labeled separately.
Economic Daily reported completion of early production-related and canine PK work. This was company-reported progress, not a human Phase I trial or completed Ministry of Agriculture review or acceptance.
Name used at publicationTian Cao Group (天草集團)
EBC News coverage of Antrodia cinnamomea research and its potential applications in companion animal health.
Name used at publicationTian Cao Group (天草集團)
FTV News coverage of the company’s Antrodia cinnamomea cultivation work and related research directions.
Name used at publicationTian Cao Group (天草集團)
Company-held TVBS clip; no official TVBS page has been located for verification.
Name used at publicationTian Cao Group (天草集團)
Economic Daily feature on the Antrodia cinnamomea industry and the development of the company’s testing standards.
Name used at publicationTian Cao Group (天草集團)
Interview on company and product development during the 2025 Asia beauty, biotechnology and health exhibition.
Name used at publicationTian Cao Group (天草集團)
Commercial Times coverage of the company’s move to OTCQB and its public-market development at the time.
Name used at publicationC.S Group / Tian Cao Group (天草集團)
FTV’s 想像台灣 program featured the Antrodia cinnamomea industry and the company’s development history.
Name used at publicationTian Cao Group (天草集團) / KASAER (天草・噶薩爾)
EBC Financial News interview with the founding team about the development of the Antrodia cinnamomea industry.
Name used at publicationTian Cao Group (天草集團) / KASAER (天草・噶薩爾)
Yahoo Taiwan branded-content feature, identified here as partnership content.
Name used at publicationTian Cao Group (天草集團) / KASAER (天草・噶薩爾)
MEDIA & PARTNERSHIPS
For company background, leadership information, interviews or partnership materials, contact TFA.
Contact us